Severe cases requiring CRRT treatment
Conditions
Interventions
Low-dose group:Anticoagulation for CRRT using nafamostat at an initial dose of 20 mL/h
High-dose group:Anticoagulation for CRRT using nafamostat at an initial dose of 50 mL/h
Sponsors
Zhujiang Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 80 years (inclusive); 2. Treatment Indication: Patients undergoing Continuous Renal Replacement Therapy (CRRT) for any cause, deemed by the attending physician to require nafamostat anticoagulation, with an anticipated dialysis duration of = 24 hours; 3. Coagulation Status: Normal coagulation function( International Normalized Ratio (INR) = 1.5 Fibrinogen (Fib) = 1.5 g/L Activated Partial Thromboplastin Time (APTT) = 45 seconds; 4. Platelet Count = 50 G/L; 5. 25>BMI>18.5kg/m²;
Exclusion criteria
Exclusion criteria: 1. Individuals with allergic constitution or known allergy to blood products, the investigational drug (nafamostat mesylate), or its excipients; 2. Patients with psychiatric disorders or other conditions that impair their ability to cooperate with treatment; 3. Patients who have used other systemic anticoagulants within 24 hours prior to or during continuous renal replacement therapy (CRRT); 4. Pregnant women, those planning pregnancy in the near future, or breastfeeding women; 5. Patients with extracorporeal circulatory support devices such as extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pump (IABP); 6. Patients with coagulation disorders;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Filter survival time; | — |
Countries
China
Contacts
Public ContactZhanguo Liu
Zhujiang Hospital of Southern Medical University
Outcome results
None listed